Repligen (RGEN) to Release Earnings on Tuesday

Repligen (NASDAQ:RGEN) is anticipated to post its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of $0.44 per share and revenue of $192.2250 million for the quarter. Parties can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 8:30 AM ET.

Repligen Trading Down 1.1%

Shares of RGEN stock opened at $135.68 on Monday. The firm has a fifty day moving average of $156.81 and a 200-day moving average of $146.56. The stock has a market cap of $7.64 billion, a price-to-earnings ratio of 6,787.39, a P/E/G ratio of 2.48 and a beta of 1.13. Repligen has a 52-week low of $102.96 and a 52-week high of $175.77. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.14 and a current ratio of 8.36.

Insider Buying and Selling

In other Repligen news, Director Karen A. Dawes sold 275 shares of the firm’s stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the sale, the director owned 91,821 shares in the company, valued at approximately $14,783,181. This trade represents a 0.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. T. Rowe Price Investment Management Inc. raised its holdings in Repligen by 12.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 646,122 shares of the biotechnology company’s stock worth $105,874,000 after purchasing an additional 74,044 shares during the period. Compound Planning Inc. acquired a new stake in Repligen during the 4th quarter worth $204,000. Invesco Ltd. lifted its holdings in Repligen by 43.9% during the fourth quarter. Invesco Ltd. now owns 1,256,439 shares of the biotechnology company’s stock worth $205,880,000 after acquiring an additional 383,399 shares in the last quarter. Alpine Woods Capital Investors LLC acquired a new position in Repligen in the fourth quarter valued at about $1,005,000. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of Repligen in the fourth quarter worth about $204,000. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

RGEN has been the subject of several recent research reports. UBS Group increased their price target on shares of Repligen from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 16th. Wall Street Zen raised Repligen from a “hold” rating to a “buy” rating in a report on Saturday, February 7th. Barclays boosted their price target on Repligen from $175.00 to $200.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Canaccord Genuity Group increased their price objective on Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research note on Wednesday, October 29th. Finally, Wells Fargo & Company lifted their price objective on Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $177.92.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.